Nilotinib Stada (Nilotinib)

Nilotinib works by selectively binding to the ATP‑binding site of the BCR‑ABL tyrosine kinase, as well as KIT and PDGFR. This inhibition blocks downstream signaling pathways that promote proliferation and survival of leukemic cells, leading to apoptosis and reduced tumor burden.

The specific dose of Nilotinib is determined by the prescribing clinician based on the patient’s condition, disease phase, and individual health factors. Dosing regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Nilotinib is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended while taking Nilotinib because the drug can be excreted in milk and may harm the infant.

To order Nilotinib Stada, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to Nilotinib is imatinib, another BCR‑ABL tyrosine kinase inhibitor. Nilotinib is generally more potent and may be effective in patients who have progressed on or are resistant to imatinib, but it also carries a higher risk of certain cardiac and metabolic side effects, requiring careful monitoring.

Nilotinib tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture. Keep the product out of direct sunlight and away from excessive heat. Do not use if the packaging is damaged or the tablets appear discolored.

Nilotinib is taken orally, usually as whole tablets with a low‑fat meal or as directed by the prescriber. The tablets should be swallowed whole with water and not chewed or crushed. Patients should follow the timing and dietary recommendations provided by their healthcare professional.

The most serious risks include QT interval prolongation leading to potentially fatal cardiac arrhythmias, severe hepatic toxicity, and pancreatitis. Patients should be monitored regularly with ECGs, liver function tests, and pancreatic enzyme assessments, and they should report any chest pain, jaundice, or severe abdominal pain promptly.

Nilotinib should not be used by individuals with a known hypersensitivity to the drug or any of its components. It is also contraindicated in patients with a history of prolonged QT interval, uncontrolled cardiac disease, or severe hepatic impairment. Pregnant or breastfeeding women should avoid use unless absolutely necessary.